Correction to: Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial

Phase Ii ◽

Metastatic Breast ◽

First Line ◽

Her2 Positive ◽

Open Label ◽

First Line Therapy ◽

Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial

Investigational New Drugs ◽

10.1007/s10637-019-00755-x ◽

2019 ◽

Vol 37 (3) ◽

pp. 538-547 ◽

Cited By ~ 3

Author(s):

Kenichi Inoue ◽

◽

Jun Ninomiya ◽

Tsuyoshi Saito ◽

Katsuhiko Okubo ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Phase Ii ◽

Metastatic Breast ◽

First Line ◽

Her2 Positive ◽

Open Label ◽

First Line Therapy ◽

Abstract P6-17-14: Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A multicenter, collaborative, open-label, phase II clinical trial for the SBCCSG-36 investigators

10.1158/1538-7445.sabcs18-p6-17-14 ◽

2019 ◽

Author(s):

K Inoue ◽

J Ninomiya ◽

K Okubo ◽

T Nakakuma ◽

H Yamada ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Metastatic Breast ◽

First Line ◽

Her2 Positive ◽

Open Label ◽

First Line Therapy ◽

Line Therapy ◽

Open Label Phase

A multinational phase II study of Navelbine (N) and Herceptin (H) as first-line therapy for patients with HER2-positive metastatic breast cancer (HER2+ MBC)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(04)90846-4 ◽

2004 ◽

Vol 2 (3) ◽

pp. 127 ◽

Cited By ~ 1

Author(s):

M Untch ◽

S Kahlert ◽

L Petruzelka ◽

M Martin ◽

V Guillem-Porta ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

First Line ◽

Her2 Positive ◽

First Line Therapy ◽

Safety, pharmacokinetics and efficacy findings in an open-label, single-arm study of weekly paclitaxel plus lapatinib as first-line therapy for Japanese women with HER2-positive metastatic breast cancer

International Journal of Clinical Oncology ◽

10.1007/s10147-015-0832-5 ◽

2015 ◽

Vol 20 (6) ◽

pp. 1102-1109 ◽

Cited By ~ 1

Author(s):

Kenichi Inoue ◽

Katsumasa Kuroi ◽

Satoru Shimizu ◽

Yoshiaki Rai ◽

Kenjiro Aogi ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Japanese Women ◽

Weekly Paclitaxel ◽

First Line ◽

Her2 Positive ◽

Open Label ◽

First Line Therapy ◽

An open-label, phase II study of weekly nab-paclitaxel as first-line therapy for patients (pts) with metastatic breast cancer (MBC): Safety update.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.1127 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 1127-1127 ◽

Cited By ~ 1

Author(s):

C. B. Brezden ◽

G. Cantin ◽

J. Younus ◽

L. C. Panasci ◽

P. Klimo ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

First Line ◽

Open Label ◽

First Line Therapy ◽

Line Therapy ◽

Open Label Phase

Trastuzumab plus docetaxel with or without capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer: a randomised Phase II study

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(08)70525-1 ◽

2008 ◽

Vol 6 (7) ◽

pp. 109-110 ◽

Cited By ~ 3

Author(s):

A. Wardlev ◽

A. Anton-Torres ◽

X. Pivot ◽

F. Morales-Vasquez ◽

L. Zetina ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Locally Advanced ◽

Metastatic Breast ◽

First Line ◽

Her2 Positive ◽

First Line Therapy ◽

Phase II Trial of Weekly Vinorelbine and Trastuzumab as First‐Line Therapy in Patients with HER2 + Metastatic Breast Cancer

The Oncologist ◽

10.1634/theoncologist.7-5-410 ◽

2002 ◽

Vol 7 (5) ◽

pp. 410-417 ◽

Cited By ~ 107

Author(s):

Mohammad Jahanzeb ◽

Joanne E. Mortimer ◽

Furhan Yunus ◽

David H. Irwin ◽

James Speyer ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

First Line ◽

First Line Therapy ◽

Final results from PERUSE, a global study of pertuzumab (P), trastuzumab (H) and investigator’s chosen taxane as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC)

10.1055/s-0041-1730221 ◽

2021 ◽

Author(s):

A Schneeweiss ◽

D Miles ◽

E Ciruelos ◽

F Puglisi ◽

T Peretz-Yablonski ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

First Line ◽

Her2 Positive ◽

First Line Therapy ◽

Line Therapy ◽

Global Study ◽

Locally Recurrent

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II and pharmacokinetic study in Japan

Anti-Cancer Drugs ◽

10.1097/cad.0b013e328302eb15 ◽

2008 ◽

Vol 19 (7) ◽

pp. 753-759 ◽

Cited By ~ 8

Author(s):

Nahomi Tokudome ◽

Yoshinori Ito ◽

Kiyohiko Hatake ◽

Masakazu Toi ◽

Muneaki Sano ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Pharmacokinetic Study ◽

Metastatic Breast ◽

First Line ◽

First Line Therapy ◽

Multicenter Phase ◽

P1-14-01: Randomized Phase II Trial of Weekly vs. q 2-Weekly vs. q 3-Weekly Nanoparticle Albumin-Bound Paclitaxel with Bevacizumab as First-Line Therapy for Metastatic Breast Cancer.

10.1158/0008-5472.sabcs11-p1-14-01 ◽

2011 ◽

Author(s):

AD Seidman ◽

AK Conlin ◽

A Bach ◽

A Forero-Torres ◽

G Wright ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Randomized Phase Ii